Silence Therapeutics (NASDAQ:SLN) Releases Earnings Results

Silence Therapeutics (NASDAQ:SLN) issued its quarterly earnings data on Thursday. The company reported ($0.32) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.14), Zacks reports. The firm had revenue of $0.42 million during the quarter, compared to analyst estimates of $1.26 million. Silence Therapeutics had a negative return on equity of 95.93% and a negative net margin of 8,943.86%.

Silence Therapeutics Stock Performance

Shares of SLN stock traded up $0.02 on Friday, reaching $6.97. 326,786 shares of the company were exchanged, compared to its average volume of 422,206. The company has a market cap of $329.19 million, a price-to-earnings ratio of -4.38 and a beta of 1.52. The business has a 50-day moving average price of $6.41 and a 200 day moving average price of $6.15. Silence Therapeutics has a 1 year low of $3.56 and a 1 year high of $8.40.

Institutional Trading of Silence Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. XTX Topco Ltd purchased a new stake in shares of Silence Therapeutics during the fourth quarter worth about $71,000. Citadel Advisors LLC purchased a new stake in shares of Silence Therapeutics during the third quarter worth about $112,000. Massar Capital Management LP purchased a new stake in shares of Silence Therapeutics during the second quarter worth about $115,000. ADAR1 Capital Management LLC increased its stake in shares of Silence Therapeutics by 26.8% during the fourth quarter. ADAR1 Capital Management LLC now owns 23,643 shares of the company’s stock worth $144,000 after purchasing an additional 5,000 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Silence Therapeutics during the fourth quarter worth about $177,000. Hedge funds and other institutional investors own 98.73% of the company’s stock.

Analyst Upgrades and Downgrades

SLN has been the subject of a number of analyst reports. HC Wainwright reiterated a “buy” rating and issued a $75.00 price objective on shares of Silence Therapeutics in a research report on Friday, March 13th. William Blair reiterated an “outperform” rating on shares of Silence Therapeutics in a research report on Monday, March 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Silence Therapeutics in a research report on Tuesday, April 21st. Finally, Jefferies Financial Group upgraded shares of Silence Therapeutics to a “strong-buy” rating in a research report on Wednesday, March 18th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $55.00.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on the discovery and development of ribonucleic acid interference (RNAi) therapeutics. Leveraging its proprietary EnCore lipid nanoparticle delivery platform, the company aims to silence disease-causing genes in the liver and other tissues. Silence’s technology is designed to enhance targeted delivery of small interfering RNA (siRNA) molecules, with the goal of achieving durable therapeutic effects and improved safety profiles compared with traditional drug modalities.

The company’s lead product candidates include SLN360, an siRNA therapeutic designed to reduce lipoprotein(a) levels for cardiovascular risk reduction, and SLN124, aimed at treating hereditary hemochromatosis and beta-thalassemia by modulating iron metabolism.